CL2019000729A1 - Proteínas de unión recombinantes y sus usos. - Google Patents
Proteínas de unión recombinantes y sus usos.Info
- Publication number
- CL2019000729A1 CL2019000729A1 CL2019000729A CL2019000729A CL2019000729A1 CL 2019000729 A1 CL2019000729 A1 CL 2019000729A1 CL 2019000729 A CL2019000729 A CL 2019000729A CL 2019000729 A CL2019000729 A CL 2019000729A CL 2019000729 A1 CL2019000729 A1 CL 2019000729A1
- Authority
- CL
- Chile
- Prior art keywords
- union
- recombinating
- associdus
- proteins
- binding proteins
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190221 | 2016-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000729A1 true CL2019000729A1 (es) | 2019-06-14 |
Family
ID=57046984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000729A CL2019000729A1 (es) | 2016-09-22 | 2019-03-21 | Proteínas de unión recombinantes y sus usos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10717772B2 (OSRAM) |
| EP (1) | EP3515933B9 (OSRAM) |
| JP (1) | JP6976335B2 (OSRAM) |
| KR (1) | KR102270315B1 (OSRAM) |
| CN (1) | CN109790206A (OSRAM) |
| AR (1) | AR109680A1 (OSRAM) |
| AU (1) | AU2017331329B2 (OSRAM) |
| BR (1) | BR112019005587A2 (OSRAM) |
| CA (1) | CA3036301C (OSRAM) |
| CL (1) | CL2019000729A1 (OSRAM) |
| CO (1) | CO2019002609A2 (OSRAM) |
| ES (1) | ES2953516T3 (OSRAM) |
| IL (1) | IL265489B (OSRAM) |
| MX (1) | MX377424B (OSRAM) |
| MY (1) | MY196882A (OSRAM) |
| NZ (1) | NZ751689A (OSRAM) |
| PH (1) | PH12019500596B1 (OSRAM) |
| SA (1) | SA519401369B1 (OSRAM) |
| WO (1) | WO2018054971A1 (OSRAM) |
| ZA (1) | ZA201901592B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139051A1 (en) | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| KR20220016944A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 개선된 안정성을 갖는 설계된 안키린 반복 도메인 |
| CA3139041A1 (en) * | 2019-06-04 | 2020-12-10 | Christian REICHEN | Recombinant 4-1bb binding proteins and their use |
| US20220242973A1 (en) * | 2019-06-04 | 2022-08-04 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| WO2021116462A1 (en) | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| TW202208404A (zh) | 2020-05-06 | 2022-03-01 | 瑞士商分子組合公司 | 新穎錨蛋白重複結合蛋白質及其用途 |
| EP4149960A1 (en) * | 2020-05-14 | 2023-03-22 | Molecular Partners AG | Recombinant cd40 binding proteins and their use |
| BR112022023049A2 (pt) | 2020-05-14 | 2022-12-20 | Molecular Partners Ag | Proteínas multiespecíficas |
| JP2023554351A (ja) | 2020-12-16 | 2023-12-27 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規の徐放性プロドラッグ |
| JP2024509890A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | プロテアーゼ切断可能なプロドラッグ |
| US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| JP2024509904A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ |
| AU2022231913A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CN119731200A (zh) | 2022-08-01 | 2025-03-28 | 分子合作伙伴股份公司 | 经电荷修饰设计的重复结构域及其用途 |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| EP2518142B1 (en) * | 2001-08-24 | 2015-07-15 | UVic Industry Partnerships Inc. | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
| DE602006010386D1 (en) | 2005-07-08 | 2009-12-24 | Univ Zuerich | Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden |
| WO2009040338A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zürich | Designed armadillo repeat proteins |
| AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| CN103459415B (zh) | 2010-11-26 | 2021-04-09 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| BR112014032316A2 (pt) | 2012-06-28 | 2017-06-27 | Molecular Partners Ag | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta |
| US10093740B2 (en) | 2012-10-15 | 2018-10-09 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| AU2016240220B2 (en) | 2015-04-02 | 2019-11-21 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
-
2017
- 2017-09-20 ES ES17778226T patent/ES2953516T3/es active Active
- 2017-09-20 CA CA3036301A patent/CA3036301C/en active Active
- 2017-09-20 AU AU2017331329A patent/AU2017331329B2/en not_active Ceased
- 2017-09-20 MY MYPI2019001523A patent/MY196882A/en unknown
- 2017-09-20 NZ NZ751689A patent/NZ751689A/en not_active IP Right Cessation
- 2017-09-20 CN CN201780058511.0A patent/CN109790206A/zh active Pending
- 2017-09-20 BR BR112019005587A patent/BR112019005587A2/pt not_active Application Discontinuation
- 2017-09-20 KR KR1020197009396A patent/KR102270315B1/ko not_active Expired - Fee Related
- 2017-09-20 JP JP2019536693A patent/JP6976335B2/ja not_active Expired - Fee Related
- 2017-09-20 US US15/710,001 patent/US10717772B2/en active Active
- 2017-09-20 AR ARP170102593A patent/AR109680A1/es not_active Application Discontinuation
- 2017-09-20 WO PCT/EP2017/073768 patent/WO2018054971A1/en not_active Ceased
- 2017-09-20 MX MX2019003298A patent/MX377424B/es active IP Right Grant
- 2017-09-20 EP EP17778226.5A patent/EP3515933B9/en active Active
- 2017-09-20 PH PH1/2019/500596A patent/PH12019500596B1/en unknown
-
2019
- 2019-03-14 ZA ZA2019/01592A patent/ZA201901592B/en unknown
- 2019-03-19 IL IL265489A patent/IL265489B/en unknown
- 2019-03-20 SA SA519401369A patent/SA519401369B1/ar unknown
- 2019-03-21 CO CONC2019/0002609A patent/CO2019002609A2/es unknown
- 2019-03-21 CL CL2019000729A patent/CL2019000729A1/es unknown
-
2020
- 2020-06-22 US US16/907,415 patent/US20210130420A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000729A1 (es) | Proteínas de unión recombinantes y sus usos. | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| CO2017009954A2 (es) | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina | |
| CL2019000628A1 (es) | Anticuerpos anti-pd-1 y sus usos. | |
| MX2018003491A (es) | Represores de htt y usos de estos. | |
| DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
| PE20170256A1 (es) | Proteinas de union y sus metodos de uso | |
| MX391249B (es) | Anticuerpos anti-muc16 y sus usos. | |
| BR112019000327A8 (pt) | Anticorpo para anticlaudina 18a2 e uso do mesmo | |
| MX2017010117A (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| DOP2018000258A (es) | Anticuerpos anti-cd40 y sus usos | |
| MX2017012380A (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| BR112018012262A2 (pt) | composições de interleucina-15 e seus usos | |
| DK3345613T3 (da) | Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel |